Efficacy and safety of Onabotulinum toxin A (Botox) injections in the upper esophageal sphincter for the treatment of Pharyngo-esophageal Dysphagia due to cricopharyngeal dysfunction- A Randomized double blinded placebo Controlled Trial

AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients attending neurology OPD with swallowing dysfunction as described above
•2. At least 14 years of age of all sexes
•3. mRS (modified Rankin scale) of <=3 at time of study enrolment
•4. In case of post stroke dysphagia, at least 6 months have passed following stroke
•5. Willing to undergo swallowing assessment clinically and with video fluoroscopy/barium swallow, flexible upper GI endoscopy and esophageal manometry before and after the injection
•6. Above investigations show impaired cricopharyngeal relaxation, adequate pharyngeal strength and antero-cephalad laryngeal movement
•7. Ready to provide consent for botulinum neurotoxin injection.
•8. Willing to adhere to protocol and comply with follow up visits
•9. No major neurologic or systemic medical condition that reduces life expectancy to less than 1 year based on clinical prediction scores

•1. Diagnosed cases of neuromuscular disorders of the peripheral nervous system and ALS
•2. mRS at time of enrolment >3
•3. Patients with expected life expectancy less than 1 year due to primary disease or co-morbidity based on clinical prediction scores
•4. Known allergy to botulinum neurotoxin or its preservatives/excipients
•5. Received botulinum toxin for any indication in the last 12 weeks
•6. Those with known antibodies against Botulinum neurotoxin A
•7. Those who underwent myotomy of the cricopharyngeus muscle
•8. Those who had undergone procedures like denervation of the cervical musculature
•9. Dysphagia of other causes not fulfilling inclusion criteria
•10. Women of childbearing potential who are not using adequate contraception or who are pregnant and lactating
•11. Not willing to provide consent

发起方